Enzo Biochem (NYSE:ENZ) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ) in a report issued on Saturday. The brokerage set a “hold” rating on the medical research company’s stock.

Enzo Biochem Price Performance

Shares of ENZ opened at $1.13 on Friday. The business has a 50-day moving average of $1.12 and a 200 day moving average of $1.13. Enzo Biochem has a fifty-two week low of $0.99 and a fifty-two week high of $1.50.

Institutional Trading of Enzo Biochem

Large investors have recently modified their holdings of the business. XTX Topco Ltd lifted its stake in Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after purchasing an additional 13,735 shares during the last quarter. Wittenberg Investment Management Inc. bought a new position in shares of Enzo Biochem in the fourth quarter worth approximately $95,000. Finally, Renaissance Technologies LLC increased its position in shares of Enzo Biochem by 2.6% in the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after acquiring an additional 64,417 shares during the period. Institutional investors own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.